Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

This study has been completed.
Information provided by:
Viventia Biotech Identifier:
First received: April 17, 2007
Last updated: December 2, 2009
Last verified: December 2009

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).

Condition Intervention Phase
Urinary Bladder Cancer
Bladder Cancer
Bladder Neoplasms
Bladder Tumors
Drug: Vicinium
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)

Resource links provided by NLM:

Further study details as provided by Viventia Biotech:

Primary Outcome Measures:
  • Treatment Schedule A: 12-Week Efficacy, Treatment Schedule B: 13-Week Efficacy [ Time Frame: 12 or 13 weeks ] [ Designated as safety issue: No ]

Enrollment: 46
Study Start Date: March 2007
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Vicinium
    Intravesical administration of Vicinium

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Disease Characteristics

  • The patient must be male or female 18 years of age or older.
  • The patient must have histologically-confirmed Transitional Cell Carcinoma (TCC) of the bladder.
  • The patient must have histologically-confirmed carcinoma in situ (CIS), with or without non-invasive papillary disease
  • The patient must have immunohistochemically-confirmed EpCAM positive disease.
  • The patient must have a life expectancy of at least 12 months.

Prior/Concurrent Therapy

  • The patient must have, within the last 24 months, failed to respond to at least 1 cycle of treatment with BCG (with or without interferon) or be intolerant to BCG treatment.
  • The patient must have had a transurethral resection of the bladder tumour (TURBT) mapping the location of tumour and quantifying the area of bladder affected.
  • The patient must have documented residual CIS (i.e. unresectable disease) prior to study drug administration.

Patient Characteristics

The patient must have adequate organ function, as defined by the clinical trial protocol


  • The patient must have the ability to understand and sign an Independent Ethics Committee or Institutional Review Board (IEC/IRB)- approved informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • The patient has evidence of urethral or upper tract transitional cell carcinoma (TCC) by biopsy or upper tract radiological imaging (i.e. intravenous pyelogram, computed tomography (CT) urogram, or retrograde pyelogram) within the past 2 years
  • The patient has hydronephrosis
  • The patient has had prior intravesical chemotherapy or investigational or anti-cancer treatments within the last 2 months, inclusive of single-dose adjuvant intravesical chemotherapy immediately post-TURBT
  • The patient has existing severe urinary tract infection or recurrent severe bacterial cystitis
  • The patient has active, uncontrolled impairment of the renal, hepatobiliary, cardiovascular, gastrointestinal, urogenital, neurologic or hematopoietic systems which, in the opinion of the investigator, would predispose the patient to the development of complications from the administration of intravesical therapy and/or general anesthesia
  • Any patient who, in the opinion of the investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of concomitant serious illness (i.e. uncontrolled cardiac or respiratory disorders)
  • The patient is pregnant or breast feeding
  • Women of reproductive age (who are not either medically or surgically incapable or bearing children) and all men may not participate unless agreeing to use double barrier contraception, or commit to abstinence during the period of therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00462488

United States, Florida
Southeastern Research Group, Inc.
Tallahassee, Florida, United States, 32308
United States, Maryland
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States, 21287
United States, New Jersey
Lawrenceville Urology
Lawrenceville, New Jersey, United States, 08648
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Oregon
Oregon Urology Institute Research
Springfield, Oregon, United States, 97477
United States, South Carolina
Grand Strand Urology
Myrtle Beach, South Carolina, United States, 29572
United States, Texas
Corpus Christi Urology Group, LLP
Corpus Christi, Texas, United States, 78404
United States, Virginia
Urology of Virginia
Newport News, Virginia, United States, 23606
Canada, British Columbia
Andreou Research
Surrey, British Columbia, Canada, V3V 1N1
Can-Med Clinical Research Inc.
Victoria, British Columbia, Canada, V8T 5G9
Canada, Ontario
The Male/Female Health and Research Centre, Royal Court Medical Centre
Barrie, Ontario, Canada, L4M 7G1
Urology Resource Centre
Burlington, Ontario, Canada, L7S 1V2
McMaster University, Institute of Urology at Saint Joseph's Hospital
Hamilton, Ontario, Canada, L8N 4A6
Centre for Applied Urological Research
Kingston, Ontario, Canada, K7L 2V7
London Health Sciences Centre
London, Ontario, Canada, N6A 4G5
The Fe/Male Health Centre
Oakville, Ontario, Canada, L6H 3P1
Todd Webster, M.D.
Owen Sound, Ontario, Canada, N4K 2J1
The Scarborough Hospital
Scarborough, Ontario, Canada, M1P 2T7
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
University of Toronto, Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Centre Hospitalier Universitaire de Sherbrooke, Hopital Fleuimont
Sherbrooke, Quebec, Canada, J1H 5N4
Sponsors and Collaborators
Viventia Biotech
Study Director: Wendy Chapman Viventia Biotech
  More Information

No publications provided by Viventia Biotech

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Wendy Chapman, Chief Operating Officer, Viventia Biotech Inc. Identifier: NCT00462488     History of Changes
Other Study ID Numbers: VB4-845-02-IIA
Study First Received: April 17, 2007
Last Updated: December 2, 2009
Health Authority: Canada: Health Canada
United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma in Situ
Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms processed this record on April 19, 2015